BioAegis Therapeutics Inc.   Report issue

For profit Phase 2
Founded: Morristown NJ United States (2011)

Organization Overview

First Clinical Trial
2018
NCT03466073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

BioAegis Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

rhu-pgelsolin (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1